Quality of life in disease-free survived patients with early-stage extranodal nasal-type NK/T-cell lymphoma after definitive intensity-modulated radiotherapy: a cross-sectional study of 310 cases.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Springer International Country of Publication: Germany NLM ID: 9302957 Publication Model: Electronic Cited Medium: Internet ISSN: 1433-7339 (Electronic) Linking ISSN: 09414355 NLM ISO Abbreviation: Support Care Cancer Subsets: MEDLINE
    • Publication Information:
      Original Publication: Berlin : Springer International, c1993-
    • Subject Terms:
      Lymphoma, Extranodal NK-T-Cell*/radiotherapy ; Radiotherapy, Intensity-Modulated*/methods ; Radiotherapy, Intensity-Modulated*/adverse effects ; Quality of Life*; Humans ; Cross-Sectional Studies ; Male ; Middle Aged ; Female ; Aged ; Adult ; Disease-Free Survival ; Surveys and Questionnaires ; Young Adult ; Adolescent ; Aged, 80 and over ; Neoplasm Staging
    • Abstract:
      Purpose: Radiotherapy is a critical treatment for early-stage extranodal nasal-type NK/T-cell lymphoma (ENKTL) and has yielded favorable survival outcomes. However, their postradiotherapy quality of life (QOL) has not been investigated. Here, we conducted a cross-sectional study to assess the QOL of ENKTL patients with disease-free survival after definitive radiotherapy and to identify factors associated with QOL and treatment optimization.
      Methods: This cross-sectional study included 310 patients with stage I-II ENKTL of the upper aerodigestive tract (UADT) who had received simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) with a consistent design and achieved disease-free survival. The median postradiotherapy time was 47.2 months (range, 3.1-115.7). The EORTC QLQ-H&N35 questionnaire was used to assess symptom-related QOL, and nine additional items were added to incorporate nasal, optical, and aural-related symptoms. The scores indicate the severity of the symptoms.
      Results: The most common postradiotherapy symptoms among patients with ENKTL were nose problems (49.7%), dry mouth (44.8%), tooth problems (41.3%), sensory problems (32.6%), and less sexuality (25.8%). Tooth problems had the highest average score of 18.6, which is still acceptable. The severity of these symptoms decreased over time and reached a plateau in the second year after radiotherapy. Multivariable regression analysis showed that whole-neck irradiation was an independent predictive factor for xerostomia (P = 0.013, OR = 1.114), while age > 60 years was a predictive factor for lower sexuality (P < 0.001, OR = 1.32).
      Conclusion: The QOL of patients with early-stage ENKTL after radiotherapy was favorable, and most symptoms improved over time. Radiotherapy was correlated with specific symptoms, which may suggest a direction for further improvement in SIB-IMRT.
      (© 2024. The Author(s).)
    • References:
      Leukemia. 2022 Jul;36(7):1720-1748. (PMID: 35732829)
      Cancers (Basel). 2022 Jan 04;14(1):. (PMID: 35008389)
      Am J Transl Res. 2021 May 15;13(5):5272-5279. (PMID: 34150118)
      Psychooncology. 2022 Mar;31(3):478-485. (PMID: 34591369)
      Radiother Oncol. 2019 Feb;131:179-185. (PMID: 30279047)
      EBioMedicine. 2017 Nov;25:41-49. (PMID: 29056540)
      Crit Rev Oral Biol Med. 2003;14(3):213-25. (PMID: 12799324)
      Radiat Oncol. 2013 Jun 25;8:152. (PMID: 23800149)
      Cancer Med. 2018 Dec;7(12):5863-5869. (PMID: 30484966)
      Am J Hematol. 2020 Sep;95(9):1047-1056. (PMID: 32449800)
      Acta Oncol. 1994;33(8):879-85. (PMID: 7818919)
      Br J Haematol. 2023 Aug;202(4):812-824. (PMID: 37394245)
      Blood. 2015 Sep 17;126(12):1424-32; quiz 1517. (PMID: 26109206)
      Cancer. 2007 Apr 15;109(8):1659-67. (PMID: 17330853)
      J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. (PMID: 8433390)
      Oncotarget. 2017 Mar 11;8(36):60504-60513. (PMID: 28947989)
      Lancet Oncol. 2018 Aug;19(8):e407-e418. (PMID: 30102235)
      Radiother Oncol. 2020 Oct;151:58-65. (PMID: 32697945)
      Front Oncol. 2021 May 07;11:665837. (PMID: 34026643)
      Blood. 2018 Jun 7;131(23):2528-2540. (PMID: 29602763)
      J Clin Oncol. 2013 Jan 10;31(2):272-9. (PMID: 23213093)
      Int J Radiat Oncol Biol Phys. 2024 Mar 1;118(3):770-780. (PMID: 37939733)
      Hematol Oncol. 2022 Dec;40(5):922-929. (PMID: 35857866)
      Oral Oncol. 2020 Jan;100:104484. (PMID: 31786391)
    • Contributed Indexing:
      Keywords: Extranodal NK/T-cell lymphoma; Postradiotherapy symptoms; Quality of life; Radiotherapy
    • Publication Date:
      Date Created: 20241014 Date Completed: 20241014 Latest Revision: 20241115
    • Publication Date:
      20241115
    • Accession Number:
      PMC11473561
    • Accession Number:
      10.1007/s00520-024-08932-2
    • Accession Number:
      39402404